Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon in Alzheimer's disease
NCT07251023Phase 3Recruiting
- Sponsor
- BIGESPAS Ltd
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latrepirdine in Alzheimer's disease (AD), sponsored by BIGESPAS Ltd. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 26 weeks. Started Nov 2025; status: recruiting.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07251023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251023.